AstraZeneca stock trades around $157 as Q2 2026 EPS beats expectations
Published on 08/14/2026 at 15:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca (ISIN US6549022043) stock is trading close to $157 in mid-August 2026, with investors weighing a recent second-quarter earnings beat and a pullback that has left the shares below key moving-average levels as of August 13, 2026.
Q2 2026 earnings beat and revenue growth
Per a detailed earnings overview dated August 14, 2026, AstraZeneca reported diluted EPS of $2.63 in Q2 2026, backed by revenue of $15.38 billion for the quarter ending June 30, 2026. The Q2 2026 earnings snapshot shows that this EPS figure was described as beating consensus expectations, underlining strong profitability during the period.
The same Q2 2026 overview notes that AstraZeneca generated $15.38 billion in revenue, indicating a scale that keeps the company among the largest global biopharmaceutical players. While the exact prior-year comparison is not spelled out in the snapshot, the characterization of an earnings beat suggests that both EPS and revenue came in above typical analyst forecasts for Q2 2026, reinforcing a constructive fundamental picture for that reporting period.
Shares steady near $157 with wide 52-week range
In the equity market, the Q2 2026 report connects directly to a price context that shows AstraZeneca shares trading at $157.40 as of August 13, 2026, 4:00 p.m. ET, with a market capitalization of $244.02 billion as of August 14, 2026. The same quote data highlights a 1-year trading range from $145.79 to $212.71, placing the current $157.40 level closer to the lower end of that 52-week band than to the top.
The Q2-linked trading snapshot also cites a 50-day moving average of $175.25 for AstraZeneca stock, meaning that the $157.40 price as of August 13, 2026 stands $17.85 below this short-term trend indicator. For investors, that gap underscores a recent pullback from earlier levels near or above the moving average, even as the fundamental backdrop has been supported by the Q2 2026 EPS beat and solid quarterly revenue.
Short-term pressure amid broader sector weakness
Recent sector commentary as of August 14, 2026 notes that major pharmaceutical constituents of the FTSE 100, including AstraZeneca, have been trading softer, with losses of more than 1 percent reported for some large-cap names over the latest session. A market summary on FTSE 100 performance points out that pharmaceutical stocks have contributed to an index decline, signalling that AstraZeneca's share-price consolidation is occurring within a broader period of sector weakness.
Additional quote data for transactions linked to AstraZeneca equity in European trading on August 14, 2026 show an intraday pattern with an open price of 31.05 in local currency, a last price of 30.85, and intraday moves spanning from 30.75 to 31.05 with a percentage change of 0.33 percent. The accessible share-graph view confirms that AstraZeneca's European listing continues to trade with moderate daily volatility, complementing the US ADR quote context.
Key product: Tagrisso as an oncology pillar
Within AstraZeneca's portfolio, oncology therapies represent a core profit driver, and the lung-cancer medicine Tagrisso is widely regarded as one of its flagship products. Contemporary investor materials describe Tagrisso as a targeted therapy for EGFR-mutated non-small cell lung cancer and highlight its contribution to the company's oncology growth story, particularly across key markets such as the United States, Europe, and Asia. For AstraZeneca, continued uptake of Tagrisso in first-line and later-line settings is an important factor underpinning revenue resilience, helping to support the EPS beat seen in Q2 2026.
Stock level and investor takeaway
As of August 13, 2026, AstraZeneca stock on the NYSE closed at $157.40 in USD, while the market cap based on subsequent data stood at $244.02 billion as of August 14, 2026. Taken together with the Q2 2026 diluted EPS of $2.63 and quarterly revenue of $15.38 billion, the current share price reflects a balance between solid reported fundamentals and ongoing sector-wide pressure that has left the stock trading below its 50-day moving average and well under the 52-week high over $212.
Fact box
Company: AstraZeneca PLC
ISIN: US6549022043
Ticker: AZN
Exchange: NYSE (ADR)
Price (as of August 13, 2026, 4:00 p.m. ET): $157.40 USD
Market cap: $244.02 billion (as of August 14, 2026)
Sector / Industry: Health care / Pharmaceuticals and biotechnology
Index membership: FTSE 100
